Showing all 5 results
Bortenat
FreeProduct Composition & Strength
We supply this product as a Sterile Lyophilized Powder in glass vials. It must be reconstituted with Normal Saline (0.9% NaCl).
Active Ingredient Strength Reference Brand Bortezomib (as Mannitol Ester) 2 mg / Vial Bortenat 2mg Bortezomib (as Mannitol Ester) 3.5 mg / Vial Bortenat 3.5mg Excipients Mannitol USP/BP Stabilizer *Pack Sizes: Single Vial Box with protective Cytotoxic shrink-wrapping.
Bortezomib Injection
FreeProduct Composition & Strength
We supply this product as a Sterile Lyophilized Powder in glass vials. It contains Mannitol, which forms a stable boronic ester with Bortezomib for shelf stability.
Active Ingredient Vial Strength Primary Use Bortezomib (as Mannitol Boronic Ester) 2 mg / Vial Single Dose / Low BSA Bortezomib (as Mannitol Boronic Ester) 3.5 mg / Vial Standard Adult Dose Excipients Mannitol (Sterile) Stabilizer / Bulking Agent *Pack Sizes: Single Vial Box with protective Cytotoxic shrink-wrapping.
ortezomib injection is an antineoplastic (cancer) medication supplied as a sterile lyophilised powder (freeze-dried cake) for reconstitution. It is most commonly known by the brand name Velcade.
Imatinib Capsules
FreeImatinib capsules contain the active oncology drug and a specific set of inactive ingredients designed to stabilize the compound for oral delivery.
Pazopanib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered, High-Density Film-Coated Tablet, packed exclusively in highly secure, child-resistant heavy-gauge HDPE bottles or specialized Alu-Alu blister strips to ensure the absolute chemical stability of the cytotoxic molecule and prevent accidental exposure.
Active Ingredient Strength Primary Clinical Function Pazopanib HCl INN/Ph.Eur. 200 mg (Base Equivalent) Dose-Modification Standard: Essential unit for precise dose reduction in patients experiencing severe hepatic toxicity or adverse drug reactions. Pazopanib HCl INN/Ph.Eur. 400 mg (Base Equivalent) Global Clinical Standard: Primary therapeutic unit designed to achieve the massive 800 mg daily protocol with minimal pill burden. Excipients Microcrystalline Cellulose / Sodium Starch Glycolate / Povidone K30 / Magnesium Stearate / Hypromellose / Titanium Dioxide Diluent / Superdisintegrant / Binder / Lubricant / Premium Cytotoxic-Barrier Film-Coating (Engineered specifically to seal the lethal HPAPI inside the tablet, completely protecting healthcare workers and caregivers from highly toxic dust exposure) *Pack Sizes: Bottles of 30 or 60 Tablets (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Sorafenib tablets 200mg
FreeA Sorafenib 200mg tablet is an oral multi-kinase inhibitor primarily containing Sorafenib as the active substance. It is used as a targeted therapy to treat advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), and certain types of thyroid cancer.
